Innate's KIR royale
BMS adds immunotherapy arm with Innate's anti-KIR mAb for cancer
With a product on the market that harnesses the adaptive immune system to attack cancer, Bristol-Myers Squibb Co. made its first move into the innate immunology space by licensing a mAb from Innate Pharma S.A. that stimulates NK cell activity.
The candidate, IPH 2102, is in a Phase I trial for acute myelogenous leukemia.
On the adaptive front, FDA approved BMS's Yervoy ipilimumab in April to treat metastatic melanoma. The mAb against